Bergamo

• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A study of ONCOFID-P-B administered intravesically to patients with Carcinoma in Situ of the bladder who have not responded to the standard … Ended recruitment
  2024-512568-72-00 5 2023-02-24 BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T
• A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L … Ended recruitment
  2024-511594-30-00 5 2023-02-23 Relapsed/Refractory Follicular Lymphoma
• An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in partici … Ended recruitment
  2023-508740-21-00 4 2023-02-15 Non-Small Cell Lung Cancer
• Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended recruitment
  2023-503501-11-00 5 2023-02-09 Metastatic Non-small Cell Lung Cancer
• RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVAL … Ended recruitment
  2024-513721-23-00 4 2022-12-15 ADVANCED TRIPLE NEGATIVE BREAST CANCER
• PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended recruitment
  2023-505057-40-00 4 2022-12-02 Lung Cancer, Non-Small Cell
• Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Ended recruitment
  2023-508284-77-00 5 2022-11-16 Generalized Myasthenia Gravis with autoantibodies against acetylcholin
• A Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with Relapsed/Refractory Multi … Ended recruitment
  2023-505865-94-00 9 2022-10-26 Relapsed/Refractory Multiple Myeloma
• A Phase 3 Study of Rusfertide (PTG-300) in Patients with Polycythemia Vera Ended recruitment
  2023-509750-58-00 5 2022-09-21 Polycythemia Vera
• A Study to Evaluate Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone o … Ended recruitment
  2023-507019-36-00 3 2022-07-08 Relapsed or Refractory Multiple Myeloma (R/R MM)
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended recruitment
  2023-503640-14-00 5 2022-02-17 Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
• Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa … Ended recruitment
  2024-518304-53-00 5 2022-02-02 Relapsed or Refractory Multiple Myeloma (RRMM)
• Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended recruitment
  2023-506867-33-01 4 2022-01-25 Chronic Hepatitis B
• A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended recruitment
  2024-511599-33-00 5 2021-12-22 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Study aimed at evaluating the efficacy of a combination treatment (decitabine and venetoclax) in patients with Acute Myeliode Leukemia who a … Ended recruitment
  2023-510241-16-00 4 2021-12-03 Acute Myeloid Leukemia secondary to myeloproliferative neoplasms
• A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance … Ended recruitment
  2023-509133-39-00 5 2021-11-29 Hormone receptor positive, HER2-negative advanced breast cancer
• Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma Ended recruitment
  2023-507381-13-00 4 2021-11-03 Relapsed/Refractory Peripheral T-Cell Lymphoma
• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended recruitment
  2023-507130-24-00 5 2021-10-22 Neovascular age-related macular degeneration (nAMD)
• Adjuvant therapy in stage IV colorectal cancer patients NED Ended recruitment
  2024-518217-26-00 4 2021-10-20 Stage IV colorectal cancer patients with no evidence of disease (NED)
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma

Showing 241–264 of 373 trials